FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202508967> ?p ?o ?g. }

• W3202508967 abstract "Objective: Assess preference of medication compared to previous treatments and clinical global impression of change (CGI-C) versus baseline in subjects using rimegepant, an orally administered small molecule CGRP receptor antagonist, in a long-term safety study for the acute treatment of migraine. Background: Preference of medication and CGI-C are clinically meaningful patient reported outcomes in trails of acute treatments for migraine. These measures have not yet been evaluated in subjects using rimegepant. Design/Methods: This was a multicenter, long-term, open-label safety study (Study 201) in adults with a history of 2–14 monthly migraine attacks of moderate to severe pain intensity. Subjects used rimegepant 75 mg orally as needed up to once daily to treat attacks of any pain intensity for 52 weeks. An exploratory objective was to assess preference of rimegepant compared to previous treatments and CGI-C relative to baseline. Improvement on CGI-C was defined by a response of very much improved, much improved, or minimally improved. Preference of medication was recorded by participants via an eDiary and CGI-C was clinician administered. Percentages are based on the number of subjects with non-missing data at the respective visit. Results: Altogether, 1514 subjects began the 52-week treatment period. Rates (95% CI) of subjects who preferred rimegepant over their previous acute treatments at week 24 (n=1027) and week 52 (n=882), were 79% (76, 81) and 80% (77, 82), respectively. Rates (95% CI) of subjects who were considered improved from baseline on the CGI-C scale at week 24 (n=1213) and week 52 (n=979), were 89% (87, 90) and 91% (89, 93), respectively. Conclusions: Over 52 weeks of acute treatment, 4 in 5 subjects preferred rimegepant to their previous migraine medications while 9 in 10 experienced clinical improvement versus baseline. Disclosure: Dr. Jensen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. Jensen holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. Croop has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharamceuticals, Inc.. Dr. Croop has received compensation for serving on the Board of Directors of Biohaven Pharamceuticals, Inc.. Dr. Croop holds stock and/or stock options in Biohaven Pharamceuticals, Inc. which sponsored research in which Dr. Croop was involved as an investigator. Dr. Croop holds stock and/or stock options in Biohaven Pharamceuticals, Inc.. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation the National Headache Foundation and Amgen.Dr. Stock has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharamceuticals. Dr. Stock holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. Thiry has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals, Inc.. Dr. Thiry has received compensation for serving on the Board of Directors of Biohaven Pharmaceuticals, Inc.. Dr. Thiry holds stock and/or stock options in Biohaven Pharmaceuticals, Inc. which sponsored research in which Dr. Thiry was involved as an investigator. Dr. Thiry holds stock and/or stock options in Biohaven Pharmaceuticals, Inc.. Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven. Dr. Conway holds stock and/or stock options in Biohaven. Dr. Lovegren has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. Lovegren holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. Coric has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals, Inc.. Dr. Coric has received compensation for serving on the Board of Directors of Biohaven Pharmaceuticals, Inc.. Dr. Coric holds stock and/or stock options in Biohaven Pharmaceuticals, Inc. which sponsored research in which Dr. Coric was involved as an investigator. Dr. Coric holds stock and/or stock options in Biohaven Pharmaceuticals, Inc.. Dr. L’Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals, Inc.. Dr. L’Italien has received compensation for serving on the Board of Directors of Biohaven Pharmaceuticals, Inc.. Dr. L’Italien holds stock and/or stock options in Biohaven Pharmaceuticals, Inc. which sponsored research in which Dr. L’Italien was involved as an investigator. Dr. L’Italien holds stock and/or stock options in Biohaven Pharmaceuticals, Inc.." @default.
• W3202508967 created "2021-10-11" @default.
• W3202508967 creator A5000448269 @default.
• W3202508967 creator A5001453416 @default.
• W3202508967 creator A5020915025 @default.
• W3202508967 creator A5054020423 @default.
• W3202508967 creator A5058152350 @default.
• W3202508967 creator A5060859207 @default.
• W3202508967 creator A5063535543 @default.
• W3202508967 creator A5067486160 @default.
• W3202508967 creator A5069362203 @default.
• W3202508967 date "2020-04-14" @default.
• W3202508967 modified "2023-09-24" @default.
• W3202508967 title "Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)" @default.
• W3202508967 hasPublicationYear "2020" @default.
• W3202508967 type Work @default.
• W3202508967 sameAs 3202508967 @default.
• W3202508967 citedByCount "0" @default.
• W3202508967 crossrefType "journal-article" @default.
• W3202508967 hasAuthorship W3202508967A5000448269 @default.
• W3202508967 hasAuthorship W3202508967A5001453416 @default.
• W3202508967 hasAuthorship W3202508967A5020915025 @default.
• W3202508967 hasAuthorship W3202508967A5054020423 @default.
• W3202508967 hasAuthorship W3202508967A5058152350 @default.
• W3202508967 hasAuthorship W3202508967A5060859207 @default.
• W3202508967 hasAuthorship W3202508967A5063535543 @default.
• W3202508967 hasAuthorship W3202508967A5067486160 @default.
• W3202508967 hasAuthorship W3202508967A5069362203 @default.
• W3202508967 hasConcept C126322002 @default.
• W3202508967 hasConcept C14184104 @default.
• W3202508967 hasConcept C142724271 @default.
• W3202508967 hasConcept C1862650 @default.
• W3202508967 hasConcept C197934379 @default.
• W3202508967 hasConcept C204787440 @default.
• W3202508967 hasConcept C27081682 @default.
• W3202508967 hasConcept C2776000289 @default.
• W3202508967 hasConcept C2778541695 @default.
• W3202508967 hasConcept C71924100 @default.
• W3202508967 hasConceptScore W3202508967C126322002 @default.
• W3202508967 hasConceptScore W3202508967C14184104 @default.
• W3202508967 hasConceptScore W3202508967C142724271 @default.
• W3202508967 hasConceptScore W3202508967C1862650 @default.
• W3202508967 hasConceptScore W3202508967C197934379 @default.
• W3202508967 hasConceptScore W3202508967C204787440 @default.
• W3202508967 hasConceptScore W3202508967C27081682 @default.
• W3202508967 hasConceptScore W3202508967C2776000289 @default.
• W3202508967 hasConceptScore W3202508967C2778541695 @default.
• W3202508967 hasConceptScore W3202508967C71924100 @default.
• W3202508967 hasLocation W32025089671 @default.
• W3202508967 hasOpenAccess W3202508967 @default.
• W3202508967 hasPrimaryLocation W32025089671 @default.
• W3202508967 hasRelatedWork W2803840290 @default.
• W3202508967 hasRelatedWork W2887885454 @default.
• W3202508967 hasRelatedWork W2950025797 @default.
• W3202508967 hasRelatedWork W2953644271 @default.
• W3202508967 hasRelatedWork W2982561889 @default.
• W3202508967 hasRelatedWork W2989973956 @default.
• W3202508967 hasRelatedWork W3018962949 @default.
• W3202508967 hasRelatedWork W3095164195 @default.
• W3202508967 hasRelatedWork W3098642271 @default.
• W3202508967 hasRelatedWork W3121083325 @default.
• W3202508967 hasRelatedWork W3171075700 @default.
• W3202508967 hasRelatedWork W3172937344 @default.
• W3202508967 hasRelatedWork W3174901842 @default.
• W3202508967 hasRelatedWork W3179338675 @default.
• W3202508967 hasRelatedWork W3183790588 @default.
• W3202508967 hasRelatedWork W3191369108 @default.
• W3202508967 hasRelatedWork W3200119531 @default.
• W3202508967 hasRelatedWork W3207790455 @default.
• W3202508967 hasRelatedWork W3209959793 @default.
• W3202508967 hasRelatedWork W3212362547 @default.
• W3202508967 hasVolume "94" @default.
• W3202508967 isParatext "false" @default.
• W3202508967 isRetracted "false" @default.
• W3202508967 magId "3202508967" @default.
• W3202508967 workType "article" @default.